Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beta Bionics (BBNX) EBITDA Margin (2024 - 2025)

Beta Bionics (BBNX) has disclosed EBITDA Margin for 2 consecutive years, with 41.77% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 4679.0% to 41.77% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 72.68% through Dec 2025, up 1151.0% year-over-year, with the annual reading at 72.68% for FY2025, 1151.0% up from the prior year.
  • EBITDA Margin hit 41.77% in Q4 2025 for Beta Bionics, up from 51.39% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 41.77% in Q4 2025 to a low of 161.47% in Q1 2025.